Literature DB >> 11551745

Iron in the Hallervorden-Spatz syndrome.

A H Koeppen1, A C Dickson.   

Abstract

The dark discoloration of globus pallidus and substantia nigra pars reticularis in the Hallervorden-Spatz syndrome is due to the accumulation of iron. Routine iron stains detect the metal mostly in microglia and macrophages, but scattered neurons are also reactive. Axonal spheroids are characteristic of the disease, and many of these expansions give a positive iron reaction. Globus pallidus and substantia nigra are normally rich in iron, and additional "storage" of the metal has often been considered the essential factor in the pathogenesis of Hallervorden-Spatz syndrome. However, other equally iron-rich structures, such as the red nucleus and the dentate nucleus, remain unaffected. In normal globus pallidus and substantia nigra pars reticularis, double-label immunofluorescence microscopy of ferritin, as an indirect marker of cellular iron localization, and phosphorylated neurofilament protein reveal close proximity of ferritin-reactive microglial and oligodendroglial processes to tightly packed axons. It is proposed that a primary axonal disorder allows the seepage of iron into the axoplasm. Iron may contribute to the axonal disease, but accumulation of the metal probably should be viewed as an epiphenomenon. Pallidal and nigral iron excess is not unique to Hallervorden-Spatz syndrome, and some previously reported postmortem examinations may actually represent pallidonigroluysian atrophy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551745     DOI: 10.1016/s0887-8994(01)00269-7

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  19 in total

1.  A novel mutation in a patient with pantothenate kinase-associated neurodegeneration.

Authors:  Danish Saleheen; Aisha Nazir; Shaheen Khanum; Shajjia Razi Haider; Philippe Frossard
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

2.  Iron localization in superficial siderosis of the central nervous system.

Authors:  Harry Kellermier; Guoji Wang; Clayton Wiley
Journal:  Neuropathology       Date:  2008-08-07       Impact factor: 1.906

Review 3.  Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes.

Authors:  Manju A Kurian; Susan J Hayflick
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

Review 4.  Neurodegeneration with brain iron accumulation.

Authors:  Allison Gregory; Susan J Hayflick
Journal:  Folia Neuropathol       Date:  2005       Impact factor: 2.038

5.  Transcranial sonography in pantothenate kinase-associated neurodegeneration.

Authors:  Vladimir S Kostić; Marina Svetel; Milija Mijajlović; Aleksandra Pavlović; Milica Ječmenica-Lukić; Duško Kozić; Dušan Kozić
Journal:  J Neurol       Date:  2011-11-05       Impact factor: 4.849

6.  Iron in neurodegenerative disorders.

Authors:  D. Berg; G. Becker; P. Riederer; O. Riess
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 7.  Clinical and genetic delineation of neurodegeneration with brain iron accumulation.

Authors:  A Gregory; B J Polster; S J Hayflick
Journal:  J Med Genet       Date:  2008-11-03       Impact factor: 6.318

8.  Case report: MR spectroscopy in pantothenate kinase-2 associated neurodegeneration.

Authors:  Umesh C Parashari; Pallavi Aga; Anit Parihar; Ragini Singh; Vindhya Joshi
Journal:  Indian J Radiol Imaging       Date:  2010-08

Review 9.  Iron homeostasis and toxicity in retinal degeneration.

Authors:  Xining He; Paul Hahn; Jared Iacovelli; Robert Wong; Chih King; Robert Bhisitkul; Mina Massaro-Giordano; Joshua L Dunaief
Journal:  Prog Retin Eye Res       Date:  2007-08-11       Impact factor: 21.198

Review 10.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.